PR Newswire BiotechOriginal article
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®
RegulatoryProSense®Positive
AI Analysis
Summary
The Society of Interventional Oncology has petitioned the NCCN to include IceCure's FDA-cleared ProSense® cryoablation technology in breast cancer treatment guidelines, expanding eligibility criteria to patients aged 50-69 who are poor surgical candidates or decline surgery.
Outcome Details
SIO petition to NCCN to include cryoablation in breast cancer treatment guidelines for patients aged 50-69 who are poor surgical candidates or decline surgery
Importance:6/10
Sentiment:
0.60
cryoablationbreast cancerFDA clearancetreatment guidelinesNCCNinterventional oncology
Read the original article
Published by PR Newswire Biotech on July 29, 2026 12:25 PM